Long term azithromycin therapy in patients with cystic fibrosis

Creative Commons License

EMİRALİOĞLU N., Öztürk Z., Yalçın E., Doğru D., Özçelik U., Kiper N.

TURKISH JOURNAL OF PEDIATRICS, cilt.58, sa.1, ss.34-40, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 58 Sayı: 1
  • Basım Tarihi: 2016
  • Doi Numarası: 10.24953/turkjped.2016.01.005
  • Dergi Adı: TURKISH JOURNAL OF PEDIATRICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.34-40
  • Anahtar Kelimeler: cystic fibrosis, inflammation, macrolide, lung function, nutrition, PSEUDOMONAS-AERUGINOSA, MAINTENANCE, MACROLIDES
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Inflammation is a central contributor to the pathogenesis of cystic fibrosis (CF) pulmonary disease; so limiting the excessive production of inflammatory mediators represents a major therapeutic strategy for slowing the decline in lung function and improving survival. The macrolide antibiotic azithromycin (AZM) has anti-inflammatory properties and immunomodulatory effects that may be beneficial in CF. The aim of this study was to document the long term use of AZM effect on pulmonary function, nutritional status and number of pulmonary exacerbations in patients with CF.